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Discovery of the endocrine function of the heart (1), which
exerts a fundamental role in regulating cardiovascular ho-
meostasis through atrial natriuretic peptide (ANP) and
B-type natriuretic peptide (BNP), has opened up a new field
of research that has resulted in multiple clinical applications
(2). The human BNP gene encodes for a pre-proBNP
olecule of 134 amino acid residues, including a signal
eptide of 26 amino acids. The BNP is cleaved out of a
rohormone molecule of 108 amino acids, the proBNP1-108
(proBNP). Before secretion from cardiomyocytes into
blood, proBNP is split by some proteolytic enzymes (prob-
ably corin and/or furin) into 2 peptides: the biologically
See page 1386
inactive NH2-terminal peptide fragment proBNP1–76 (NT-
roBNP), and the COOH-terminal peptide fragment
roBNP77–108 (BNP), which is the active hormone, binding
specific receptors (NPR-A, -B, -C) (2,3). In addition to
bioactive BNP, a huge number of circulating proBNP-
derived fragments can be identified by chromatographic
procedures in human plasma (4), including the intact
precursor proBNP1–108, found in a significant amount in
stage C and stage D heart failure (HF) patients (3–5). Liang
et al. (6) demonstrated that proBNP, constituting a sub-
stantial portion of immunoreactive BNP in plasma of HF
patients, possesses significantly lower biological activity than
the 32-amino acid hormone.
The widespread diffusion of automated assays of BNP
and NT-proBNP has furnished a novel tool for diagnosis,
prognostic evaluation, and guide to treatment of overt HF,
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relationships to disclose.as well for the screening of asymptomatic left ventricular
dysfunction in the general population (2,7), with a potential
use in primary care (8). Recent evidence has challenged,
however, the specificity of all commercial assays for BNP
and NT-proBNP, indicating a significant cross-reactivity
with the precursor proBNP1–108, variable for each assay (9).
his means that, beyond their proven diagnostic accuracy
nd prognostic value in HF, those assays are not specific for
heir declared target, with evident implications for the
athophysiological and clinical interpretation of data, not
et completely understood.
In this issue of the Journal, Macheret et al. (10) measured
n the general community the circulating intact precursor
roBNP1–108 by means of a highly specific proBNP1–108
sandwich immunoassay (11). They evaluated its ability to
detect left ventricular systolic dysfunction, in comparison
with commercial BNP and NT-proBNP assays, in a cohort
of 1,939 subjects (672 healthy subjects and 1,267 stages A to C
HF patients, 45 years of age), undergoing clinical and
echocardiographic characterization. The method used is
based on a specific monoclonal antibody recognizing the
cleavage site of proBNP1–108, without any significant cross-
reactivity with either recombinant NT-proBNP1–76 or syn-
thetic BNP1–32, combined with a polyclonal antibody di-
ected against BNP1–32 (11).
Macheret et al. (10) demonstrated that proBNP1–108 was
detectable in all subjects studied, and its level was dependent
on sex, age, heart rate, and body mass index. Furthermore,
they found that the degree of sensitivity and specificity of
the proBNP assay for the detection of left ventricular
dysfunction was comparable to 2 commercial assays for
BNP and NT-proBNP (10).
This study confirms and extends previous evidence (5)
that the intact precursor of biologically active BNP (i.e., the
proBNP1–108) circulates in plasma of both healthy subjects
and HF patients, and underscores the diagnostic usefulness
of its assay (5), which has been previously shown to hold
prognostic value in patients with systolic HF, too (12).
Moreover, circulating levels of proBNP1–108 are age- and
sex-dependent and progressively increase with disease se-
verity in HF patients, as previously reported for BNP and
NT-proBNP measured by commercial immunoassays (2,3,13).
Two potential drawbacks are evidenced by the Macheret
study (10): the automated proBNP immunoassay is not
commercially available, and may not be considered, at this
moment, for current clinical use, especially in emergency
departments. Moreover, this study was not able to demon-
strate a better diagnostic accuracy of proBNP for left
ventricular dysfunction, as compared with a currently used
NT-proBNP assay.
However, the high specificity of this proBNP assay for
targeted molecules and its overall good diagnostic accuracy
as shown in this study pave the way for a future use of this
biomarker, as an alternative to other BNP assays currently
used for screening of left ventricular dysfunction in asymp-
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differential diagnosis in patients with dyspnea. Evidence is
growing, supporting an out-of-hospital use of natriuretic
peptide assays: their implementation in screening programs
and diagnostic algorithms in primary care might contribute
to decrease the apparent disparity between the general
practitioner and the specialist approach to disease manage-
ment (8).
Indeed, the findings by Macheret et al. (10) indicate that
the greater part of B-type natriuretic peptides assayed in HF
patients is devoid of biological activity. As a whole, these
results (10) support the hypothesis that the post-
translational maturation processing of ventricular proBNP
is not efficient in HF (2,15,16).
The BNP gene is expressed in both atrial and ventricular
myocytes of normal and diseased hearts (1,2,14). Ventricu-
lar myocytes do not usually display any evident secretory
granules at electron microscopy in normal heart, whereas
some granules, similar to the atrial ones, can be found in
samples of ventricular myocardium collected during surgery
or in endocardial biopsies (2,3). That suggests that normal
ventricular myocardium may produce only a limited amount
of biologically active BNP1–32 in response to an acute,
fficacious stimulation, probably through a constitutive se-
retory pathway, while the amount of hormone produced
nd secreted after chronic stimulation in patients with HF
ight be greatly increased through an up-regulated secre-
ory pathway (10,14). According to this hypothesis, a huge
mount of immunoreactive BNP circulating in plasma of
F patients and measurable with conventional BNP and
T-proBNP immunoassays is not biologically active. That
ay add to the understanding of the resistance to the
iological effects of natriuretic hormones (the “natriuretic
aradox”), which plays an important role in the pathophys-
ology of sodium retention and systemic and renal vasocon-
triction observed in severe HF, substantially contributing
o disease progression (2,3,15).
At present, the exact reason for proBNP1–108 processing
eficiency in HF is unknown, but an enzymatic deficiency,
ither due to saturation or constitutive dysfunction, might
nderlie the progression from asymptomatic cardiac dys-
unction to overt HF (2). The hypothesis of a “cardiac
ndocrine dysfunction” may support the high variability of
linical HF phenotypes, given a similar etiology and extent
f cardiac damage/dysfunction. However, it is well known
hat infusion of the same ANP or BNP dose has a reduced
atriuretic effect in HF patients, as compared to healthy
ubjects. This observation suggests that there are also other
eceptorial and post-receptorial mechanisms causing the
esistance to natriuretic hormone action, including down-
egulation of A and B natriuretic receptors, up-regulation of
learance NPR-C receptors, or post-receptor issues, such as
ncreased activity of cyclic guanosine monophosphate-
hosphodiesterase, which metabolizes cyclic guanosine
onophosphate (2,16). aConversely, it is theoretically conceivable that the
OOH-terminal fragment including the cysteine bond
i.e., the active hormone BNP1–32) may be produced even in
ivo from the circulating intact precursor proBNP by plasma
nzyme degradation. Although there is no demonstration
hat circulating proBNP can be processed in vivo in human
lood, a soluble form of corin, a transmembrane serine
rotease able to cleave both proANP and proBNP, may be
lso capable of processing the circulating intact precursor of
atriuretic hormones (17). Dong et al. (18) recently con-
rmed that soluble corin is measurable in human blood.
urthermore, these investigators reported that plasma corin
evels are significantly lower in HF patients than in healthy
ontrols and that the reduction in plasma enzyme correlates
ith the severity of the disease (18). These preliminary
bservations, if confirmed, suggest a more complex scenario
egarding the “natriuretic paradox”: the circulating intact
recursor proBNP might be actually considered a prohor-
one, processed into the active peptide, when necessary
17,18). This hypothesis assumes that the peripheral pro-
essing of circulating proBNP would be submitted to
egulatory rules, possibly altered with HF progression. This
bnormality might be considered as a possible future ther-
peutic target, for example, by studying drugs inducing the
leavage of the prohormone into active BNP.
Although the assay of proBNP (a more stable molecule
ith higher molecular weight than derived peptides) has
ome theoretical advantages, from an analytical point of
iew, once automated assays will be available, 1 important
ssue could facilitate its diffusion in the clinical setting. As a
uture perspective, the simultaneous measurement in the
ame plasma sample with 2 methods, 1 specific for the intact
recursor proBNP1–108, and the other for active peptide
NP1–32, could allow a more accurate estimate of the true
activity of cardiac natriuretic hormone system as compared
with the single assay of either peptide (4,9), likely extending
our present understanding of pathophysiological and clinical
changes due to cardiac endocrine dysfunction on HF evo-
lution. Indeed, a recent study of ambulatory patients with
chronic systolic HF showed that the combined assessment
of conventional BNP and proBNP immunoassays provides
additional information in determining the risk of adverse
clinical outcomes, particularly in patients with low BNP
values (12). Conversely, the proposal by Macheret et al. (10)
of considering proBNP/NT-proBNP ratio, based on an
electrochemiluminescent immunoassay of NT-proBNP, as
a useful interpretative tool is questionable. Actually, this
ratio does not reflect either the ratio between the prohor-
mone and the biologically active hormone or the true
relationship between the prohormone and NT-proBNP
peptide level, because of the cross-reactivity of the NT-
proBNP method used with proBNP, as mentioned by the
authors themselves.
In summary, a proBNP1–108 assay shows several features
f the ideal biomarker (in vivo and in vitro stability,
dequate analytical-functional sensitivity, reproducibility,
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plete assay automation, demonstration of low biological
variation, reference range and cut-off values tested for sex,
age, and ethnicity dependence, extensively proven good
diagnostic and prognostic accuracy, evaluation of cost effec-
tiveness). Our interest in this “novel” natriuretic peptide
assay is in its specificity for the molecule targeted, whereas
at present all conventional BNP and NT-proBNP immu-
noassays, showing some cross-reactivity with the intact
precursor proBNP, may be considered, at the same time,
accurate markers of HF presence and severity, and inaccu-
rate indexes of BNP biological activity (9). Diagnostic
manufacturers should set up specific immunoassay methods
for biologically active BNP1–32 peptide, to overcome this
mportant drawback. Thereafter, designed studies would be
ecessary to estimate and compare the diagnostic and
rognostic accuracy of specific assays for different B-type
elated peptides: BNP, NT-proBNP, and intact proBNP,
sed either alone or in combination.
Reprint requests and correspondence: Dr. Michele Emdin,
Cardiovascular Medicine Division, Fondazione G. Monasterio
CNR-Regione Toscana, Via Giuseppe Moruzzi 1, Pisa 56124,
Italy. E-mail: emdin@ftgm.it.
REFERENCES
1. de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and
potent natriuretic response to intravenous injection of atrial myocardial
extract in rats. Life Sci 1981;28:89–94.
2. Clerico A, Recchia FA, Passino C, Emdin M. Cardiac endocrine
function is an essential component of the homeostatic regulation
network: physiological and clinical implications. Am J Physiol Heart
Circ Physiol 2006;290:H17–29.
3. Goetze JP. Biosynthesis of cardiac natriuretic peptides. Results Probl
Cell Differ 2010;50:97–120.
4. Seferian KR, Tamm NN, Semenov AG, et al. The brain natriuretic
peptide (BNP) precursor is the major immunoreactive form of BNP in
patients with heart failure. Clin Chem 2007;53:866–73.5. Mogelvang R, Goetze JP, Schnohr P, et al. Discriminating between
cardiac and pulmonary dysfunction in the general population withdyspnea by plasma pro-B-type natriuretic peptide. J Am Coll Cardiol
2007;23;50:1694–701.
6. Liang F, O’Rear J, Schellenberger U, et al. Evidence for functional
heterogeneity of circulating B-type natriuretic peptide. J Am Coll
Cardiol 2007;49:1071–8.
7. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update
incorporated into the ACC/AHA 2005 guidelines for the diagnosis
and management of heart failure in adults: a report of the American
College of Cardiology Foundation/American Heart Association Task
Force on Practice Guidelines. J Am Coll Cardiol 2009;53:e1–90.
8. Emdin M, Fontana M, Poletti R, et al. Natriuretic peptide testing in
primary care patients. Clin Chem Lab Med 2008;46:1533–42.
9. Luckenbill KN, Christenson RH, Jaffe AS, et al. Cross-reactivity of
BNP, NT-proBNP, and proBNP in commercial BNP and NT-
proBNP assays: preliminary observations from the IFCC Committee
for Standardization of Markers of Cardiac Damage. Clin Chem
2008;54:619–21.
0. Macheret F, Boerrigter G, McKie P, et al. Pro–B-type natriuretic
peptide1–108 circulates in the general community: plasma determinants
and detection of left ventricular systolic dysfunction. J Am Coll
Cardiol 2011;57:1386–95.
11. Giuliani I, Rieunier F, Larue C, et al. Assay for measurement of intact
B-type natriuretic peptide prohormone in blood. Clin Chem 2006;52:
1054–61.
12. Dries DL, Ky B, Wu AH, Rame JE, Putt ME, Cappola TP.
Simultaneous assessment of unprocessed ProBNP1-108 in addition to
processed BNP32 improves identification of high-risk ambulatory
patients with heart failure. Circ Heart Fail 2010;3:220–7.
13. Clerico A, Emdin M. Diagnostic accuracy and prognostic relevance of
the measurement of the cardiac natriuretic peptides: a review. Clin
Chem 2004;50:33–50.
14. McGrath MF, de Bold AJ. Determinants of natriuretic peptide gene
expression. Peptides 2005;26:933–43.
15. Chen HH. Heart failure: a state of brain natriuretic peptide deficiency
or resistance or both! J Am Coll Cardiol 2007;49:1089–91.
16. Forfia PR, Lee M, Tunin RS, Mahmud M, Champion HC, Kass DA.
Acute phosphodiesterase 5 inhibition mimics hemodynamic effects of
B-type natriuretic peptide and potentiates B-type natriuretic peptide
effects in failing but not normal canine heart. J Am Coll Cardiol
2007;49:1079–88.
17. Knappe S, Wu F, Masikat MR, et al. Functional analysis of the
transmembrane domain and activation cleavage of human corin: design
and characterization of a soluble corin. J Biol Chem 2003;278:52363–70.
18. Dong N, Chen S, Yang J, et al. Plasma soluble corin in patients with
heart failure. Circ Heart Fail 2010;3:207–11.Key Words: biomarker y BNP y heart failure y NT-proBNP y
proBNP.
